Literature DB >> 16519545

Trends in outpatient prescription drug use and related costs in the US: 1998-2003.

Diane K Wysowski1, Laura A Governale, Joslyn Swann.   

Abstract

OBJECTIVE: To present a brief synopsis of trends in the number of prescriptions and retail costs of outpatient drugs dispensed in the US between 1998 and 2003.
METHODS: Data were extracted from IMS Health, the National Prescription Audit Plus and the National Disease and Therapeutic Index databases.
RESULTS: In 1998, 2.7 billion outpatient prescriptions were dispensed versus 3.6 billion in 2003. This equates to a 33.3% increase over the 6-year period. Of the top 20 most dispensed drugs by volume, 40% were launched in the 1990s or 2000s. Retail costs for the total market of dispensed outpatient prescription drugs were 96.1 billion US dollars in 1998 and 196 billion US dollars in 2003, a 104% increase. Of the top 20 most dispensed drugs by retail cost, all were tradename drugs and were launched in the 1990s or 2000s.
CONCLUSIONS: These data indicate a large increase in the US over a short time period in dispensed outpatient prescriptions and their associated retail costs.

Entities:  

Mesh:

Year:  2006        PMID: 16519545     DOI: 10.2165/00019053-200624030-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  2 in total

1.  Retail prescription drug spending in the National Health Accounts.

Authors:  Cynthia Smith
Journal:  Health Aff (Millwood)       Date:  2004 Jan-Feb       Impact factor: 6.301

2.  Use of menopausal hormones in the United States, 1992 through June, 2003.

Authors:  Diane K Wysowski; Laura A Governale
Journal:  Pharmacoepidemiol Drug Saf       Date:  2005-03       Impact factor: 2.890

  2 in total
  6 in total

1.  Field test results of a new ambulatory care Medication Error and Adverse Drug Event Reporting System--MEADERS.

Authors:  John Hickner; Atif Zafar; Grace M Kuo; Lyle J Fagnan; Samuel N Forjuoh; Lyndee M Knox; John T Lynch; Brian Kelly Stevens; Wilson D Pace; Benjamin N Hamlin; Hilary Scherer; Brenda L Hudson; Caitlin Carroll Oppenheimer; William M Tierney
Journal:  Ann Fam Med       Date:  2010 Nov-Dec       Impact factor: 5.166

2.  Using spatial analysis to demonstrate the heterogeneity of the cardiovascular drug-prescribing pattern in Taiwan.

Authors:  Ching-Lan Cheng; Yi-Chi Chen; Tzu-Ming Liu; Yea-Huei Kao Yang
Journal:  BMC Public Health       Date:  2011-05-24       Impact factor: 3.295

3.  The Selective Serotonin Reuptake Inhibitor Fluoxetine Directly Inhibits Osteoblast Differentiation and Mineralization During Fracture Healing in Mice.

Authors:  Vivian Bradaschia-Correa; Anne M Josephson; Devan Mehta; Matthew Mizrahi; Shane S Neibart; Chao Liu; Oran D Kennedy; Alesha B Castillo; Kenneth A Egol; Philipp Leucht
Journal:  J Bone Miner Res       Date:  2017-02-27       Impact factor: 6.741

4.  Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk.

Authors:  Phoebe G Thorpe; Suzanne M Gilboa; Sonia Hernandez-Diaz; Jennifer Lind; Janet D Cragan; Gerald Briggs; Sandra Kweder; Jan M Friedman; Allen A Mitchell; Margaret A Honein
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-07-29       Impact factor: 2.890

5.  Surveillance of prescription drug-related mortality using death certificate data.

Authors:  Diane K Wysowski
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

6.  Improving accuracy of medication identification in an older population using a medication bottle color symbol label system.

Authors:  Roberto Cardarelli; Christopher Mann; Kimberly G Fulda; Elizabeth Balyakina; Anna Espinoza; Sue Lurie
Journal:  BMC Fam Pract       Date:  2011-12-29       Impact factor: 2.497

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.